NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/03/2024
Back to search
Official data from USPTO
NANT CANCER VACCINE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
NANT CANCER VACCINE
ST13
US500000097599709Class
5
Filing
97599709
Registration
7491160
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
22
Latest update
09/03/2024
Classification
Registered
Trademark type
Word
Nice classes
5
Filing date
09/20/2022
Registration date
09/03/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/03/2024
Last transaction
09/03/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
07/19/2022
First use in commerce
07/19/2022
Drawing code
4
Owner type
16
Owner location
Culver City, CA
Examiner
ALTREE, NICK
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Nant Holdings IP, LLC
Representatives
Michael J. McCue LEWIS ROCA ROTHGERBER CHRISTIE LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
pharmaceutical preparations and substances for the treatment of human diseases in the nature of non-cancerous neoplasia, immunologic-related diseases, and immunologic dysfunction, animal diseases, autoimmune diseases, infectious diseases and cancer for scientific, clinical, medicinal, therapeutic, and diagnostic purposes; pharmaceutical preparations and substances for the prevention, diagnosis, and treatment of human diseases in the nature of non-cancerous neoplasia, immunologic-related diseases, and immunologic dysfunction, animal diseases, autoimmune diseases, infectious diseases and cancer; pharmaceutical and biological preparations for use in targeted immunotherapy for the treatment of human diseases in the nature of non-cancerous neoplasia, immunologic-related diseases, and immunologic dysfunction, animal diseases, autoimmune diseases, infectious diseases and cancer; biological preparations for medical purposes, namely, vaccine preparations; low-dose chemotherapeutics, low dose radiopharmaceutical preparations, and personalized neoepitope-targeted pharmaceutical preparations for medical use for the treatment of human diseases in the nature of non-cancerous neoplasia, immunologic-related diseases, and immunologic dysfunction, animal diseases, autoimmune diseases, infectious diseases, and cancer; anti-cancer preparations; vaccines; biological preparations, namely, cell-derived preparations, cell therapeutics, monoclonal antibodies, cytokines, immune modulators, low-dose chemotherapeutics, low-dose radiation therapeutics, antibodies, fusion proteins, peptide and cytokine biological preparations, vaccines, personalized neoepitope-based therapeutics, and natural killer cell derived preparations, for the treatment of non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, autoimmune diseases, infectious diseases, animal diseases, and cancer for clinical, medicinal, therapeutic, and veterinary purposes; kits comprising cell cultures, reagents and related instructions, for use in the treatment and prevention of non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, autoimmune diseases, infectious diseases, animal diseases and cancer, for clinical, medicinal, therapeutic and veterinary purposes
Publications
History of USPTO decisions and trademark events.
22 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
09/03/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/18/2024
PUBO
PUBLISHED FOR OPPOSITION
06/18/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/29/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/14/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
05/14/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
05/14/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
05/14/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
05/14/2024
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
02/15/2024
GNFR
FINAL REFUSAL E-MAILED
02/15/2024
CNFR
FINAL REFUSAL WRITTEN
02/15/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/21/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/21/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/21/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/21/2023
GNRT
NON-FINAL ACTION E-MAILED
08/21/2023
CNRT
NON-FINAL ACTION WRITTEN
08/21/2023
DOCK
ASSIGNED TO EXAMINER
06/29/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/26/2022
NWAP
NEW APPLICATION ENTERED
09/23/2022
Continuous trademark protection
Get notified about every new filing that threatens NANT CANCER VACCINE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.